To be held at 22nd - 23rd January 2009, BSG Conference Centre, London, UK
Key Speakers
Dr Matthew Baker, Chief Scientific Officer, Antitope
Dr David Blakey, Chief Scientist, Oncology, AstraZeneca / MedImmune
Dr Michael Kragh, Director of Antibody Pharmacology, Symphogen
Dr. Christian Klein, Department Head Discovery Oncology, Pharma Research, Roche Diagnostics
Dr Rathin C. Das, President, Affitech USA, Senior VP Corp Development & CBO, Affi tech Group
Dr Frederic Fellouse, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
Dr René Hoet, Sr. Director, Research, Genmab
Dr Candi Soames, Partner, Edwards Angell Palmer & Dodge
Dr David R. Buckler, Director of Research Alliances, Dyax
Philippe Stas, CEO, Algonomics, President, European Immunogenicity Platform
Dr Michael Steward, Manager, Biopharm CEDD Domantis
Professor Serge Muyldermans, VIB Department of Molecular and Cellular Interactions, Vrije Universiteit Brussel
Dr Ulrich Rothbauer, BioCenter, Department of Biology, Ludwig Maximilians University
Dr Philip Webber, European Patent Attorney, Frank B Dehn
Dr Hilde Revets, Director Cell Biology and Immunology, Ablynx
Dear Colleague,
The protein therapeutics market remains one of the fastest growing segments of the pharma market, and recombinant antibodies have gained enormous importance for clinical applications. Visiongain’s greatly anticipated event will enable you to examine these current applications, and latest developments in the fi eld of antibody engineering. Recombinant antibodies have distinct advantages compared with conventional antibodies such as, rapid growth and ease of manipulation, making them the ideal choice for expression of non-glycosylated peptides and proteins. Innovative product classes such as alternative binding molecules will further expand their use, whilst novel engineered production hosts and integrated technology platforms hold huge potential for future applications. By attending Visiongain’s 2nd Annual Recombinant Antibodies Conference you will gain a comprehensive outlook for the protein therapeutics market from product development to strategic issues and market trends.
Reasons to register today:
• Hear from key researchers and decision makers in the field of antibody engineering
• Examine the current market environment for therapeutic antibodies and assess market potential
• Discover recent developments in antibody display and selection techniques
• Understand the regulatory requirements for recombinant therapeutic antibodies and hear strategies for protecting antibodies
• Learn practical measures for predicting and minimising immunogenicity
• Identify potential protein therapeutics areas for partnerships and collaboration
• Be part of a unique networking opportunity
I look forward to meeting you at the conference.
Best regards
Andrea Charles
Head of Conferences
Who should attend:
VPs, Directors, Heads and Managers of:
• Research & Development
• Protein Engineering
• Antibody Engineering
• Preclinical Development
• Clinical Development
• Antibody Development
• Immunology (Research)
• Immunogenicity
• (Clinical) Oncology
• Oncology Research
• Oncology Discovery
• IP/ Patents
• New Product Development
• Business Development
• Marketing
• Licensing
For more information kindly visit: http://www.bharatbook.com/
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
